<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107594">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01901263</url>
  </required_header>
  <id_info>
    <org_study_id>1208125</org_study_id>
    <secondary_id>13.069bis</secondary_id>
    <nct_id>NCT01901263</nct_id>
  </id_info>
  <brief_title>Patients With Behavioural Symptoms and Hospitalized in Cognitive and Behavioural Units</brief_title>
  <official_title>Initial and Long-term Evaluation of Patients With Behavioural Symptoms and Hospitalized in Cognitive and Behavioural Units</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agence Régionale de la Santé - Rhône Alpes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <authority>France: French Data Protection Authority</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cognitive and behavioral units (CBUs) have been created between 2008 and 2012 French
      National Alzheimer plan for the management of behavior problems of patients suffering from
      Alzheimer's disease or other related disorders and necessitating hospitalisation. This
      Alzheimer plan is promoting the evaluation of these units through the observation of the
      behavioral and psychological symptoms of dementia (BPSD) evolution.  As these units are new,
      it appears important to assess their long-term impact on patients care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      EXPECTED RESULTS The present study should allow to better understand the long-term impact of
      CBU on care of patients with Alzheimer disease and BPSD. Moreover, it should allow to
      identify patients improved by CBU.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Neuropsychiatric Inventory (NPI) score</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
    <description>impact of CBU effectiveness in reducing BPSD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CBU effectiveness in reducing BPSD</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CBU effectiveness on quality of life of patients and caregivers, and on caregivers' burden</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Psychotropic drugs (in particular neuroleptic drugs) consumption</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rehospitalisation rate for BPSD of the patients in the year following their hospitalisation in CBU</measure>
    <time_frame>one year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">306</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>patient with alzheimer's disease</arm_group_label>
    <description>Cohort of patients with psychological symptoms of dementia hospitalised in Cognitive and Behaviorial Units (CBUs)
Evaluation of these units through the observation of the behavioral and psychological symptoms of dementia evolution : NPI score, caregivers quality of life, caregivers burden, collection of psychotropic drugs, the rehospitalisation rate</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>patients with alzheimer's disease</intervention_name>
    <description>the Neuropsychiatric Inventory (NPI), is uded to assess 10 behavioral disturbances occurring in dementia patients: delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, and aberrant motor activity. The NPI uses a screening strategy to minimize administration time, examining and scoring only those behavioral domains with positive responses to screening questions.</description>
    <arm_group_label>patient with alzheimer's disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Alzheimer's disease or associated disorders and BDSP and hospitalized in a
        CBU
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient hospitalized on CBUs

          -  patient with the diagnostic criteria for disease related to dementia stage with a
             Clinical Demential Rating ≥ 1

          -  patient with a caregiver who is fairly frequent contact with the patient in order to
             observe the appearance of behavior changes

        Exclusion Criteria:

          -  Patient living alone at home

          -  Patient with risk of death within one year
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle ROUCH, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Saint-Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabelle ROUCH, PhD</last_name>
    <phone>(0)477127398</phone>
    <phone_ext>+33</phone_ext>
    <email>isabelle.rouch@chu-st-etienne.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CH Saint Jean de Dieu</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florence Dibie‐Racoupeau, MD</last_name>
      <phone>04 37 90 12 01</phone>
    </contact>
    <investigator>
      <last_name>Florence Dibie‐Racoupeau</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cédric Granet</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Rouch, MD</last_name>
      <email>isabelle.rouch@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Rouch</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chantal Girtanner</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Villeurbanne</city>
        <zip>69100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Géraldine Martin‐Gaujard, MD</last_name>
      <phone>04 72 43 20 50</phone>
    </contact>
    <investigator>
      <last_name>Géraldine Martin‐Gaujard</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 28, 2014</lastchanged_date>
  <firstreceived_date>July 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cognitive and behavioral units</keyword>
  <keyword>Alzheimer Disease</keyword>
  <keyword>Dementia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Behavioral Symptoms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
